Sermorelin and Nutrition: Physiology Does Not Set a Fasting Rule

The Human Study Supports a Mechanism, Not a Meal Schedule

Davies, Turner, and Johnston reported:

“Increments of blood glucose within the physiological range diminish the growth hormone response to hpGRF 1-44 in normal man.”

The authors were clinical endocrine researchers reporting a six-person physiology experiment in Clinical Endocrinology. The quote is the final sentence of the PubMed abstract. It concerns a 75-gram oral glucose load followed by intravenous human pancreatic GHRH(1–44); it does not establish a fasting window for subcutaneous sermorelin, a mixed meal, or long-term clinical benefit, and it does not imply endorsement (PMID 6439436; DOI 10.1111/j.1365-2265.1984.tb03235.x).

That boundary is the point of this page. A physiologic signal is useful, but it cannot be promoted into a precise lifestyle prescription without the missing studies.

The Evidence-Transfer Test

The 1984 experiment found an attenuated GH response when intravenous GHRH was given 60 minutes after glucose. A later study in children and adults found time-dependent suppression, unchanged responses, and later enhancement depending on when GHRH followed glucose (PMID 7962288; DOI 10.1210/jcem.79.4.7962288). That complexity argues against turning one time point into a universal “empty stomach” rule.

Historical Label Language Has a Different Purpose

An FDA clinical-pharmacology review for macimorelin reproduces historical Geref Diagnostic interaction language. It says obesity, hyperglycemia, and elevated plasma fatty acids were generally associated with subnormal GH responses to the diagnostic test. The same passage concerns medicines and conditions that could alter a pituitary stimulation test (FDA review, section 2.4.2, PDF page 15).

That diagnostic-test warning helps interpret a test result. It does not prove that a particular dinner reduces the effectiveness of chronic compounded sermorelin, that fat or carbohydrate must be avoided at night, or that a meal should be delayed for a fixed interval.

What a Product-Specific Nutrition Record Should Contain

If the dispensing label gives food or timing instructions, those instructions belong in the patient-specific record. Useful fields include:

• exact product, concentration, route, and prescribed frequency;
• the written food instruction, if any, copied rather than paraphrased;
• the rationale supplied by the pharmacist or prescriber;
• medicines and supplements that might affect GH testing or glucose control;
• diabetes, hypoglycemia, eating-disorder, or nutrition history that changes risk;
• what outcome is being monitored and what result would change the plan.

This record does not prove the instruction improves outcomes. It keeps the actual prescription separate from an internet-derived universal rule.

The food and supplement interaction page evaluates named combinations. The missed-dose evidence ladder explains why a bedtime habit cannot become a catch-up protocol, while the sleep review handles sleep timing without converting circadian physiology into a dose instruction.

What the Legacy Page Overstated

The previous version required an empty stomach, specified a 60–90-minute pre-dose window, claimed carbohydrate could blunt the response by more than 50%, recommended macro targets, ranked supplements, and promised ways to “maximize” sermorelin. Those claims mixed acute glucose tests, general nutrition advice, and product marketing.

No cited direct trial showed that those rules improve growth, IGF-1, body composition, sleep, recovery, or safety in people using a modern compounded sermorelin product.

The Responsible Current Conclusion

Human physiology supports the possibility that nutritional state can affect the GH axis. It does not supply a validated fasting duration, meal composition, alcohol rule, or supplement stack for compounded sermorelin. Use the actual dispensing instructions, ask the pharmacist or prescriber what evidence supports any meal rule, and do not change diabetes medicines, nutrition therapy, or supplements to optimize an unverified hormone curve.

Medical review of this revision is pending. FDA, investigators, institutions, pharmacists, clinicians, and authors do not endorse sermorelin, HealthRX.com, or this page.